|
1.
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2.
|
Gillison ML, Koch WM, Capone RB, et al:
Evidence for a causal association between human papillomavirus and
a subset of head and neck cancers. J Natl Cancer Inst. 92:709–720.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
D’Souza G, Kreimer AR, Viscidi R, et al:
Case-control study of human papillomavirus and oropharyngeal
cancer. N Engl J Med. 356:1944–1956. 2007.PubMed/NCBI
|
|
4.
|
Applebaum KM, Furniss CS, Zeka A, et al:
Lack of association of alcohol and tobacco with HPV16-associated
head and neck cancer. J Natl Cancer Inst. 99:1801–1810. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Gillison ML, D’Souza G, Westra W, et al:
Distinct risk factor profiles for human papillomavirus type
16-positive and human papillomavirus type 16-negative head and neck
cancers. J Natl Cancer Inst. 100:407–420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Smith EM, Ritchie JM, Summersgill KF, et
al: Age, sexual behavior and human papillomavirus infection in oral
cavity and oropharyngeal cancers. Int J Cancer. 108:766–772. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Näsman A, Attner P, Hammarstedt L, et al:
Incidence of human papillomavirus (HPV) positive tonsillar
carcinoma in Stockholm, Sweden: an epidemic of viral-induced
carcinoma. Int J Cancer. 125:362–366. 2009.PubMed/NCBI
|
|
8.
|
McLaughlin-Drubin ME and Munger K:
Oncogenic activities of human papillomaviruses. Virus Res.
143:195–208. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Li X and Coffino P: High-risk human
papillomavirus E6 protein has two distinct binding sites within
p53, of which only one determines degradation. J Virol.
70:4509–4516. 1996.PubMed/NCBI
|
|
10.
|
Talis AL, Huibregtse JM and Howley PM: The
role of E6AP in the regulation of p53 protein levels in human
papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem.
273:6439–6445. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Dyson N: The regulation of E2F by
pRB-family proteins. Genes Dev. 12:2245–2262. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Münger K, Basile JR, Duensing S, et al:
Biological activities and molecular targets of the human
papillomavirus E7 oncoprotein. Oncogene. 20:7888–7898.
2001.PubMed/NCBI
|
|
13.
|
Bouvard V, Matlashewski G, Gu ZM, Storey A
and Banks L: The human papillomavirus type 16 E5 gene cooperates
with the E7 gene to stimulate proliferation of primary cells and
increases viral gene expression. Virology. 203:73–80. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Schwarz E, Freese UK, Gissmann L, et al:
Structure and transcription of human papillomavirus sequences in
cervical carcinoma cells. Nature. 314:111–114. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Smith EM, Rubenstein LM, Haugen TH,
Pawlita M and Turek LP: Complex etiology underlies risk and
survival in head and neck cancer human papillomavirus, tobacco and
alcohol: a case for multifactor disease. J Oncol.
5718622012.PubMed/NCBI
|
|
16.
|
Fakhry C, Westra WH, Li S, et al: Improved
survival of patients with human papillomavirus positive head and
neck squamous cell carcinoma in a prospective clinical trial. J
Natl Cancer Inst. 100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Gillison ML, Harris J, Westra W, et al:
Survival outcomes by tumor human papillomavirus (HPV) status in
stage III–IV oropharyngeal cancer (OPC) in RTOG 0129. Proc Am Soc
Clin Oncol. 27:60032009.
|
|
18.
|
Chung CH and Gillison ML: Human
papillomavirus in head and neck cancer: its role in pathogenesis
and clinical implications. Clin Cancer Res. 15:6758–6762. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Brennan JA, Boyle JO, Koch WM, et al:
Association between cigarette smoking and mutation of the p53 gene
in squamous-cell carcinoma of the head and neck. N Engl J Med.
332:712–717. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Carlos de Vicente J, Junquera Gutiérrez
LM, Zapatero AH, Fresno Forcelledo MF, Hernández-Vallejo G and
López Arranz JS: Prognostic significance of p53 expression in oral
squamous cell carcinoma without neck node metastases. Head Neck.
26:22–30. 2004.PubMed/NCBI
|
|
21.
|
Khademi B, Shirazi FM, Vasei M, et al: The
expression of p53, c-erbB-1 and c-erbB-2 molecules and their
correlation with prognostic markers in patients with head and neck
tumors. Cancer Lett. 184:223–230. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Licitra L, Perrone F, Bossi P, et al:
High-risk human papillomavirus affects prognosis in patients with
surgically treated oropharyngeal squamous cell carcinoma. J Clin
Oncol. 24:5630–5636. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kumar B, Cordell KG, Lee JS, Worden FP, et
al: EGFR, p16, HPV Titer, Bcl-xL and p53, sex and smoking as
indicators of response to therapy and survival in oropharyngeal
cancer. J Clin Oncol. 26:3128–3137. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Scheffner M, Werness BA, Huibregtse JM,
Levine AJ and Howley PM: The E6 oncoprotein encoded by human
papillomavirus types 16 and 18 promotes the degradation of p53.
Cell. 63:1129–1136. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Wiest T, Schwarz E, Enders C,
Flechtenmacher C and Bosch FX: Involvement of intact HPV16 E6/E7
gene expression in head and neck cancers with unaltered p53 status
and perturbed pRb cell cycle control. Oncogene. 21:1510–1517. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Westra WH, Taube JM, Poeta ML, Begum S,
Sidransky D and Koch WM: Inverse relationship between human
papillomavirus-16 infection and disruptive p53 gene mutations in
squamous cell carcinoma of the head and neck. Clin Cancer Res.
14:366–369. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Lee EJ, Kim J, Lee SA, et al:
Characterization of newly established oral cancer cell lines
derived from six squamous cell carcinoma and two mucoepidermoid
carcinoma cells. Exp Mol Med. 37:379–390. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Hafkamp HC, Mooren JJ, Claessen SM, et al:
P21Cip1/WAF1expression is strongly associated with
HPV-positive tonsillar carcinoma and a favorable prognosis. Mod
Pathol. 22:686–698. 2009.
|
|
29.
|
Kessis TD, Slebos RJ, Nelson WG, et al:
Human papillomavirus 16 E6 expression disrupts the p53-mediated
cellular response to DNA damage. Proc Natl Acad Sci USA.
90:3988–3992. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Martinez I, Wang J, Hobson KF, Ferris RL
and Khan SA: Identification of differentially expressed genes in
HPV-positive and HPV-negative oropharyngeal squamous cell
carcinomas. Eur J Cancer. 43:415–432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Pyeon D, Newton MA, Lambert PF, et al:
Fundamental differences in cell cycle deregulation in human
papillomavirus-positive and human papillomavirus-negative head/neck
and cervical cancers. Cancer Res. 67:4605–4619. 2007. View Article : Google Scholar
|
|
32.
|
Lohavanichbutr P, Houck J, Fan W, et al:
Genomewide gene expression profiles of HPV-positive and
HPV-negative oropharyngeal cancer: potential implications for
treatment choices. Arch Otolaryngol Head Neck Surg. 135:180–188.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Kaczkowski B, Rossing M, Andersen DK, et
al: Integrative analyses reveal novel strategies in HPV11, -16 and
-45 early infection. Sci Rep. 2:5152012. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Lai SY and Johnson FM: Defining the role
of the JAK-STAT pathway in head and neck and thoracic malignancies:
Implications for future therapeutic approaches. Drug Resist Updat.
13:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Hong S, Mehta KP and Laimins LA:
Suppression of STAT-1 expression by human papillomaviruses is
necessary for differentiation-dependent genome amplification and
plasmid maintenance. J Virol. 85:9486–9494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Boccardo E, Manzini Baldi CV, Carvalho AF,
et al: Expression of human papillomavirus type 16 E7 oncoprotein
alters keratinocytes expression profile in response to tumor
necrosis factor-α. Carcinogenesis. 31:521–531. 2010.PubMed/NCBI
|
|
38.
|
Smeets SJ, van der Plas M, Schaaij-Visser
TB, van Veen EA, et al: Immortalization of oral keratinocytes by
functional inactivation of the p53 and pRb pathways. Int J Cancer.
128:1596–1605. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Shim SH, Sung MW, Park SW and Heo DS:
Absence of STAT1 disturbs the anticancer effect induced by STAT3
inhibition in head and neck carcinoma cell lines. Int J Mol Med.
23:805–810. 2009.PubMed/NCBI
|
|
40.
|
Xi S, Dyer KF, Kimak M, et al: Decreased
STAT1 expression by promoter methylation in squamous cell
carcinogenesis. J Natl Cancer Inst. 98:181–189. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Laimer K, Spizzo G, Obrist P, et al: STAT1
activation in squamous cell cancer of the oral cavity: a potential
predictive marker of response to adjuvant chemotherapy. Cancer.
110:326–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Riebe C, Pries R, Schroeder KN and
Wollenberg B: Phosphorylation of STAT3 in head and neck cancer
requires p38 MAPKinase, whereas phosphorylation of STAT1 occurs via
a different signaling pathway. Anticancer Res. 31:3819–3825.
2011.PubMed/NCBI
|
|
43.
|
Barnes CJ, Ohshiro K, Rayala SK, El-Naggar
AK and Kumar R: Insulin-like growth factor receptor as a
therapeutic target in head and neck cancer. Clin Cancer Res.
13:4291–4299. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Bähr C and Groner B: The IGF-1 receptor
and its contributions to metastatic tumor growth-novel approaches
to the inhibition of IGF-1R function. Growth Factors. 23:1–14.
2005.PubMed/NCBI
|
|
45.
|
Boulenouar S, Weyn C, Van Noppen M, et al:
Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion,
migration and invasion of trophoblastic cells. Carcinogenesis.
31:473–480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Epshtein A, Jackman A, Gonen P and Sherman
L: HPV16 E6 oncoprotein increases cell adhesion in human
keratinocytes. Arch Virol. 154:55–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Einstein MH, Schiller JT, Viscidi RP, et
al: Clinician’s guide to human papillomavirus immunology: knowns
and unknowns. Lancet Infect Dis. 9:347–356. 2009.
|
|
48.
|
Won HS, Jung CK, Chun SH, et al:
Difference in expression of EGFR, pAkt and PTEN between
oropharyngeal and oral cavity squamous cell carcinoma. Oral Oncol.
48:985–990. 2012. View Article : Google Scholar : PubMed/NCBI
|
